AbbVie Inc. (ABBV)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
115.78+1.88 (+1.65%)
At close: 4:02PM EDT
115.50 -0.31 (-0.27%)
Pre-market: 9:19AM EDT
| Previous close | 113.90 |
| Open | 114.31 |
| Bid | 115.40 x 800 |
| Ask | 116.88 x 800 |
| Day's range | 113.95 - 116.28 |
| 52-week range | 79.11 - 116.28 |
| Volume | 6,708,155 |
| Avg. volume | 6,906,616 |
| Market cap | 204.332B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 39.75 |
| EPS (TTM) | 2.91 |
| Earnings date | 29 Jul 2021 - 02 Aug 2021 |
| Forward dividend & yield | 5.20 (4.49%) |
| Ex-dividend date | 14 Apr 2021 |
| 1y target est | 123.78 |
- Zacks
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
Is (ABBV) Outperforming Other Medical Stocks This Year?
- Zacks
AbbVie (ABBV) Stock Moves -0.61%: What You Should Know
AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.
- Motley Fool
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.
© 2021 Verizon Media. All rights reserved.
